Welcome to the PROteKT Trial Website
PROteKT is a Phase IIa, Randomised, Controlled, Open-Label Trial of Rosuvastatin for the Prevention of Aminoglycoside-Induced Kidney Toxicity in Children with Cystic Fibrosis
Trial Sponsor: University of Liverpool.
Trial Funders: The J P Moulton Charitable Foundation and the North West England MRC Clinical Pharmacology and Therapeutic Fellowship awarded to Dr S McWilliam.
Trial Coordination: The University of Liverpool Clinical Trials Research Centre (data management and statistics) and the University College of London (trial management).